J
Jan A. Burger
Researcher at University of Texas MD Anderson Cancer Center
Publications - 543
Citations - 33028
Jan A. Burger is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic lymphocytic leukemia & Ibrutinib. The author has an hindex of 83, co-authored 511 publications receiving 28306 citations. Previous affiliations of Jan A. Burger include University of Texas Health Science Center at Houston & University of Freiburg.
Papers
More filters
Journal ArticleDOI
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia
Farhad Ravandi,Susan O'Brien,Deborah A. Thomas,Stefan Faderl,Dan Jones,Rebecca Garris,Samuel Dara,Jeffrey L. Jorgensen,Partow Kebriaei,Richard E. Champlin,Gautam Borthakur,Jan A. Burger,Alessandra Ferrajoli,Guillermo Garcia-Manero,William G. Wierda,Jorge E. Cortes,Hagop M. Kantarjian +16 more
TL;DR: The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL, with an estimated 2-year survival of 64%.
Journal ArticleDOI
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells
Meike Burger,Tanja Nicole Hartmann,Tanja Nicole Hartmann,Myriam Krome,Myriam Krome,Justyna Rawluk,Justyna Rawluk,Hirokazu Tamamura,Hirokazu Tamamura,Nobutaka Fujii,Nobutaka Fujii,Thomas J. Kipps,Thomas J. Kipps,Jan A. Burger,Jan A. Burger +14 more
TL;DR: It is demonstrated that CXCR4 blocking agents effectively antagonize CXCL12-induced migratory and signaling responses and stromal protection of CLL cells from spontaneous or fludarabine-induced apoptosis and small molecular CX CR4 antagonists may have activity in the treatment of patients with this disease.
Journal ArticleDOI
CXCR4 is a prognostic marker in acute myelogenous leukemia
TL;DR: CXCR4 expression in AML is an independent prognostic predictor for disease relapse and survival that can rapidly and easily be determined at disease presentation and should be incorporated into the risk assessment of AML patients.
Journal ArticleDOI
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Preetesh Jain,Preetesh Jain,Michael J. Keating,William G. Wierda,Zeev Estrov,Alessandra Ferrajoli,Nitin Jain,Binsah George,Danelle F. James,Hagop M. Kantarjian,Jan A. Burger,Susan O'Brien +11 more
TL;DR: Most patients with RR-CLL who discontinued ibrutinib early were difficult to treat and had poor outcomes.
Journal ArticleDOI
Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia.
Wan Zhang,Dunyaporn Trachootham,Dunyaporn Trachootham,Jinyun Liu,Gang Chen,Helene Pelicano,Celia Garcia-Prieto,Weiqin Lu,Jan A. Burger,Carlo M. Croce,William Plunkett,Michael J. Keating,Peng Huang +12 more
TL;DR: A biochemical mechanism by which bone marrow stromal cells modulate the redox status of chronic lymphocytic leukaemia (CLL) cells and promote cellular survival and drug resistance is shown.